Number of employees
78
Annual revenue
$967333
Novavax Inc. is a biotechnology company committed to leading the global fight against infectious diseases by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbreak. Our team has created vaccines designed to protect against various circulating strains of avian influenza as well as seasonal flu. We have validated our approach in animals and are moving toward clinical testing.